- Home
- HOPE vs ORKA Comparison
HOPE vs ORKA Comparison
Compare HOPE & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOPE
- ORKA
- Stock Information
- Founded
- HOPE 1986
- ORKA 2004
- Country
- HOPE United States
- ORKA United States
- Employees
- HOPE N/A
- ORKA N/A
- Industry
- HOPE Major Banks
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HOPE Finance
- ORKA Health Care
- Exchange
- HOPE Nasdaq
- ORKA Nasdaq
- Market Cap
- HOPE 1.4B
- ORKA 1.2B
- IPO Year
- HOPE 1996
- ORKA N/A
- Fundamental
- Price
- HOPE $10.47
- ORKA $26.86
- Analyst Decision
- HOPE Buy
- ORKA Strong Buy
- Analyst Count
- HOPE 2
- ORKA 7
- Target Price
- HOPE $13.25
- ORKA $42.86
- AVG Volume (30 Days)
- HOPE 756.1K
- ORKA 619.0K
- Earning Date
- HOPE 10-28-2025
- ORKA 11-12-2025
- Dividend Yield
- HOPE 5.12%
- ORKA N/A
- EPS Growth
- HOPE N/A
- ORKA N/A
- EPS
- HOPE 0.34
- ORKA N/A
- Revenue
- HOPE $412,692,000.00
- ORKA N/A
- Revenue This Year
- HOPE $17.88
- ORKA N/A
- Revenue Next Year
- HOPE $11.76
- ORKA N/A
- P/E Ratio
- HOPE $32.12
- ORKA N/A
- Revenue Growth
- HOPE N/A
- ORKA N/A
- 52 Week Low
- HOPE $8.83
- ORKA $5.49
- 52 Week High
- HOPE $14.54
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- HOPE 42.22
- ORKA 76.91
- Support Level
- HOPE $10.52
- ORKA $24.46
- Resistance Level
- HOPE $11.13
- ORKA $29.20
- Average True Range (ATR)
- HOPE 0.27
- ORKA 2.05
- MACD
- HOPE -0.03
- ORKA 0.79
- Stochastic Oscillator
- HOPE 10.40
- ORKA 84.55
About HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services and other banking services.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.